HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro
- PMID: 21822119
- DOI: 10.1097/CAD.0b013e32834a2c70
HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro
Abstract
Our aim was to analyze the impact of the histone deacetylase (HDAC)-inhibitor valproic acid (VPA) on bladder cancer cell growth in vitro. RT-4, TCCSUP, UMUC-3, and RT-112 bladder cancer cells were treated with VPA (0.125-1 mmol/l) without and with preincubation periods of 3 and 5 days. Controls remained untreated. Tumor cell growth, cell cycle progression, and cell cycle-regulating proteins were investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, flow cytometry, and western blotting, respectively. Effects of VPA on histone H3 and H4 acetylation and HDAC3 and HDAC4 were also determined. Without preincubation, no tumor cell growth reduction was observed with 0.125 and 0.25 mmol/l VPA in TCCSUP, UMUC-3, and RT-112 cells, whereas 0.5 and 1 mmol/l VPA diminished the cell number significantly. VPA (0.25 mmol/l) did exert tumor growth-blocking effects after a 3-day preincubation. To achieve antitumor effects with VPA (0.125 mmol/l), a 5-day preincubation was necessary. A 3-day or 5-day preincubation was also necessary to distinctly delay cell cycle progression, with maximum effects at VPA (1 mmol/l). After the 5-day preincubation, the cell cycle-regulating proteins cdk1, cdk2, cdk4, and cyclins B, D1, and E were reduced, whereas p27 was enhanced. Diminished HDAC3 and 4 expression induced by VPA was accompanied by elevated acetylation of H3 and H4. VPA exerted growth-blocking properties on a panel of bladder cancer cell lines, commensurate with dose and exposure time. Long-term application induced much stronger effects than did shorter application and should be considered when designing therapeutic strategies for treating bladder carcinoma.
Similar articles
-
HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions.Exp Biol Med (Maywood). 2013 Nov 1;238(11):1297-304. doi: 10.1177/1535370213498975. Epub 2013 Sep 4. Exp Biol Med (Maywood). 2013. PMID: 24006305
-
Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.Prostate. 2012 Dec 1;72(16):1719-35. doi: 10.1002/pros.22525. Epub 2012 Apr 2. Prostate. 2012. PMID: 22473339
-
Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.Prostate. 2011 May 15;71(7):722-35. doi: 10.1002/pros.21288. Epub 2010 Oct 15. Prostate. 2011. PMID: 20954195
-
Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells.J Immunol Res. 2019 Mar 14;2019:9678098. doi: 10.1155/2019/9678098. eCollection 2019. J Immunol Res. 2019. PMID: 31001564 Free PMC article. Review.
-
Hidden pharmacological activities of valproic acid: A new insight.Biomed Pharmacother. 2021 Oct;142:112021. doi: 10.1016/j.biopha.2021.112021. Epub 2021 Aug 25. Biomed Pharmacother. 2021. PMID: 34463268 Review.
Cited by
-
Neuroprotective effects of psychotropic drugs in Huntington's disease.Int J Mol Sci. 2013 Nov 15;14(11):22558-603. doi: 10.3390/ijms141122558. Int J Mol Sci. 2013. PMID: 24248060 Free PMC article. Review.
-
Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression.BMC Urol. 2012 Aug 16;12:21. doi: 10.1186/1471-2490-12-21. BMC Urol. 2012. PMID: 22898175 Free PMC article.
-
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma.Aging (Albany NY). 2016 Jun;8(6):1236-49. doi: 10.18632/aging.100980. Aging (Albany NY). 2016. PMID: 27295551 Free PMC article.
-
Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.J Mol Med (Berl). 2018 Dec;96(12):1307-1318. doi: 10.1007/s00109-018-1697-7. Epub 2018 Oct 4. J Mol Med (Berl). 2018. PMID: 30288546
-
Evaluation of cell death pathways initiated by antitumor drugs melatonin and valproic acid in bladder cancer cells.FEBS Open Bio. 2017 Apr 27;7(6):798-810. doi: 10.1002/2211-5463.12223. eCollection 2017 Jun. FEBS Open Bio. 2017. PMID: 28593135 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous